Alivus Life Sciences Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 18.4%)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ALIVUS · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 82.85% | 82.85% | 82.85% | 75.00% | 75.00% | 74.99% |
| FII | 4.57% | 5.01% | 4.81% | 7.85% | 6.74% | 6.57% |
| DII | 0.74% | 1.41% | 1.57% | 4.16% | 4.86% | 5.19% |
| Public | 11.84% | 10.73% | 10.76% | 12.99% | 13.40% | 13.25% |
Corporate Events
Inter-alia to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026
Dividend - Rs 5 Per Share
To consider and approve the financial results for the period ended June 30, 2026
Dividend - Rs 5 Per Share
Interim Dividend - Rs 22.50 Per Share
Annual General Meeting
Latest News
All newsAlivus Life Sciences incorporates wholly owned subsidiary in Brazil
*Alivus Life Sciences incorporates wholly owned subsidiary in Brazil* to strengthen its international footprint. The move marks a strategic expansion into the Brazilian market. While no financial figures were disclosed, this step could support long-term growth. 📊 *STOCKS:* $ALIVUS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Expansion
Alivus Life Sciences to host investor meet
*Alivus Life Sciences to host investor meet.* The company has announced a schedule for its analyst and institutional investor meet. Details from the call may provide insights into business strategy and financial outlook. No major operational or financial updates were disclosed. 📊 *STOCKS:* $ALIVUS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Alivus Life Sciences to host analyst meet
*Alivus Life Sciences to host analyst and institutional investor meet.* The event aims to provide updates on company performance and strategy. No financial figures or major announcements disclosed. Likely to support investor engagement without immediate price catalysts. 📊 *STOCKS:* $ALIVUS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Alivus Life Sciences to host analyst and investor meet
*Alivus Life Sciences to host analyst and investor meet.* The company announced a scheduled interaction with institutional investors and analysts. Such meets are routine and typically used to update stakeholders on business performance and outlook. No major financial announcements were disclosed. 📊 *STOCKS:* $ALIVUS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Alivus Life Sciences declares dividend record date
*Alivus Life Sciences declares dividend record date.* The company has set **01-Sep-2026** as the record date for dividend disbursement. Shareholders registered on this date will be eligible for dividends. Final payment details will follow in due course. 📊 *STOCKS:* $ALIVUS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Alivus Life Sciences to hold shareholder meeting.
*Alivus Life Sciences to hold shareholder meeting.* The company has scheduled a meeting on **September 08, 2026**, as per its NSE filing. Such meetings typically address routine corporate matters or approvals. No material financial figures or strategic shifts were disclosed. 📊 *STOCKS:* $ALIVUS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting
Alivus Life Sciences hosts investor call
*Alivus Life Sciences hosts investor call* to discuss business updates. The company shared insights during an analyst and institutional investor meet. Recording of the call is available online for review. No major financial figures or announcements were highlighted. 📊 *STOCKS:* $ALIVUS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorCall
About Alivus Life Sciences Limited
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
HealthcarePharmaceuticals & Biotechnology